Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
03/2007
03/28/2007EP1765831A1 Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
03/28/2007EP1765815A2 New compounds useful for treating cns disorders
03/28/2007EP1765779A1 New substituted piperidines as modulators of dopamine neurotransmission
03/28/2007EP1499312B1 The use of hydroxypyridone-derivatives in wound healing
03/28/2007CN1307181C Condensed heterocyclic succimide compounds as androgen receptor modulators and their analog
03/28/2007CN1307173C Pyrimidineamines as angiogenesis modulators
03/28/2007CN1307157C Novel compounds
03/27/2007US7196109 Piperidine-1-carboxylic acid (6,7-difluoro-5-phenyl-1H-indazol-3-yl)amide; especially for treating neurodegenerative diseases; kinase inhibitor
03/27/2007US7196096 Substituted amines of spirofuropyridines useful in therapy
03/27/2007US7196091 Tyrosine kinase inhibitors; controlling signal transduction; antitumor agents; benign prostate hyperplasia; respiratory system disorders
03/27/2007US7196079 for treating, headache, migraine or cluster headache
03/27/2007CA2193460C 3-amino-2-mercaptobenzoic acid derivatives and processes for their preparation
03/22/2007US20070066655 Diarylmethylidene piperidine derivatives and their use as delta opiod receptor agonists
03/22/2007US20070066642 Novel imidazopyridine compound ii with therapeutic effect
03/22/2007US20070066600 Compounds
03/22/2007US20070066599 New compounds
03/22/2007US20070066598 Compounds
03/21/2007EP1692153A4 Inhibition of syk kinase expression
03/21/2007EP1425282B1 Process for the preparation of diketopyrrolopyrroles
03/21/2007CN1934099A N-piperidine derivates as CCR3 modulators
03/21/2007CN1933835A Methods of preventing weight gain
03/20/2007US7192979 EP4 receptor selective agonist in the treatment of osteoporosis
03/20/2007US7192963 Janus Kinase 3 inhibitors; organ transplant rejection, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia, and autoimmune diseases
03/15/2007US20070060627 Organic compounds
03/15/2007US20070060583 2-tert-Butyl-N,N-diethyl-1-{[1-methylpiperidin-2-yl]methyl}-1H-benzimidazole-5-carboxamide; cannabinoid receptors agonists; analgesic, anticarcinogenic, antiinflammatory, anxiolytic agent; neurodegenerative diseases; gastrointestinal and cardiovascular disorders
03/15/2007US20070060572 e.g., 2-(5-fluoro-2-tolyl)-4-(4-aminocarbonylpiperazinylmethyl)-6-[a-aminocarbonyl-2,6-dichlorobenzyl]pyridine; mitogen-activated protein kinase inhibitor; antiinflammatory agent, autoimmune diseases
03/14/2007EP1762567A1 Pyrazole derivatives for treating HIV
03/14/2007EP1761531A1 Imidazole variants as modulators of gaba receptor for the treatment of gi disorders
03/14/2007EP1761530A1 New derivatives of 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxamide or 5-aryl-1h-pyrrolo [2, 3b] pyridine-3-carboxylic acid
03/14/2007EP1761494A1 Chemical compounds i
03/14/2007EP1761491A1 Novel piperidine/8-azabicyclo [3.2.1] octan derivatives as moduilators of chemokine receptor ccr5
03/14/2007CN1304375C Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
03/14/2007CN1303913C Method for producing an avocado unsaponifiable rich in furan lipids
03/13/2007US7190991 Multi-mode internal imaging
03/13/2007CA2315227C Arylpiperazines having activity at the serotonin 1a receptor
03/08/2007US20070054921 Substituted indoles and a process for preparing substituted indoles
03/08/2007US20070054917 Piperazine derivates and their use for the treatment of neurological and psychiatric diseases
03/08/2007US20070054847 Use of adnf polypeptides for treating anxiety and depression
03/07/2007EP0959076B1 Heteroarylperidines and piperazines and their use as antipsychotics and analgetics
03/07/2007CN1926141A Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics
03/07/2007CN1926132A Pyrazole compounds useful as protein kinase inhibitors
03/07/2007CN1926122A Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
03/07/2007CN1926108A Non-nucleotide reverse transcriptase inhibitors
03/07/2007CN1923835A Polymorphs of clopidogrel hydrogensulfate
03/06/2007US7186847 Process for the direct preparation of pyrrolo[3,4-c]pyrroles
03/06/2007US7186830 Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
03/06/2007CA1341521C 1-hydroxyethyl-azole derivatives, a process for their preparation and their use as plant growth regulators and fungicides
03/01/2007WO2005030711A3 Bridged macrocyclic module compositions
03/01/2007US20070049755 Novel triazolo pyrimidine compounds
03/01/2007US20070049600 Pteridinones as kinase inhibitors
03/01/2007US20070049558 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
03/01/2007US20070048215 Chemical compound and assay
02/2007
02/28/2007EP1757601A1 Quinoline derivatives and their use in glaucoma and myopia
02/28/2007EP1756111A1 Alkyl substituted indoloquinoxalines
02/28/2007EP1756061A1 Therapeutic compounds: pyridine n oxide scaffold
02/28/2007EP1756060A1 Therapeutic compounds: pyridine as scaffold
02/28/2007EP1756044A1 Therapeutic compounds
02/28/2007EP1581538B1 Tetracyclic 3-substituted indoles having serotonin receptor affinity
02/28/2007EP1465893B1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo (3.2.1) octane, the preparation thereof and the application of same in therapeutics
02/28/2007EP1392666B1 Biologically active methylene blue derivatives
02/28/2007CN1922169A Spirocyclic heterocyclic derivatives and methods of their use
02/28/2007CN1920050A Method of resolution of 1,3-oxathiolane nucleoside enantiomers
02/28/2007CN1301977C Preparation of aminopyrimidine compounds
02/28/2007CN1301963C Process for producing N-(4-fluobenzene radical)-N-(2-hydroxy-4-chlorobenzene group) glycocoll
02/27/2007US7183312 Compounds for use as antigrowth agents or antitumor agents and with solvents
02/27/2007US7183304 Heterocyclic compounds and methods of use
02/22/2007WO2007022529A2 Method of treating inflammatory diseases
02/22/2007US20070043084 1,2-Diarylimidazoles useful as inhibitors of cox
02/22/2007US20070043038 Indolone-acetamide derivatives, processes for preparing them and their uses
02/21/2007EP1754707A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes
02/21/2007EP1753736A2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
02/21/2007EP1511727B1 Aromatic sulfones and their medical use
02/21/2007EP1458690B1 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
02/21/2007EP1355905B1 Pyrazole compounds useful as protein kinase inhibitors
02/21/2007CN1918169A Cysteine protease inhibitors
02/21/2007CN1918149A Novel chelating agents and highly luminescent and stable chelates and their use
02/21/2007CN1918147A 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof
02/21/2007CN1918124A New pyridin-2-one compounds useful as inhibitors of thrombin
02/21/2007CN1915016A Pesticidal formulation
02/20/2007US7179910 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
02/20/2007US7179823 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
02/20/2007US7179802 reducing the risk of developing a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia
02/20/2007CA2455050C Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
02/15/2007WO2006134219A3 Atipamezhole hydrochloride crystallization method
02/15/2007US20070037859 Substituted Thiazolidinedione Derivative, Process for Its Preparation and Its Pharmaceutical Use
02/15/2007US20070037830 2-Adamantyl derivatives as p2X7 receptor antagonists.
02/14/2007EP1751172A1 Novel 3-triazolyl-galactoside inhibitors of galectins
02/14/2007EP1751171A1 Novel galactoside inhibitors of galectins
02/14/2007EP1345928B1 Pyrazole compounds useful as protein kinase inhibitors
02/14/2007CN1914225A HCV NS-3 serine protease inhibitors
02/14/2007CN1914224A HCV NS-3 serine protease inhibitors
02/14/2007CN1911930A Chemokine receptor anagonists, methods and use therefor
02/14/2007CN1911928A Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, the preparation thereof and the application of same in therapeutics
02/13/2007US7176308 Purification; chemical synthesis; photosensitive coloring material; use for coating an optical disc for copy-protection
02/13/2007US7176242 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives
02/13/2007US7176220 Useful as an anti-HIV agent that particularly shows an anti-HIV action based on an integrase inhibitory activity; for treatment or prophylaxis of AIDS; for example, 6-(2,3-dichlorobenzyl)-1-(2-hydroxyethyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
02/13/2007US7176214 Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
02/13/2007US7176202 Such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide; purinergic receptors (P2x7 E); for treatment of interleukin-1 associated disorders, rheumatoid arthritis
02/13/2007CA2359744C Cephalosporins and homologues preparations and pharmaceutical compositions
02/13/2007CA2359510C .omega.-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
1 ... 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ... 105